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Molecular alterations at chromosome 9p21 in 
melanocytic naevi and melanoma
Several studies suggest that 
molecular alterations at 
chromosome 9p21, mainly 
involving the CDKN locus 
and its p16 (CDKN2A) 
tumour suppressor gene, 
play a role in melanoma 
pathogenesis. Based on 
fluorescence in situ hybrid-
ization and immunohis-
tochemistry analyses on 
naevi, primary and meta-
static melanomas, this 
study defined the time of onset for such molecular alterations 
during the sequential phases of melanocytic tumorigenesis. 
Allelic deletions at chromosome 9p21 seem to represent an 
early event, participating in melanoma initiation, where-
as the p16 (CDKN2A) gene seems to be inactivated dur-
ing tumour progression, contributing to a more aggressive 
behaviour of melanomas. Br J Dermatol 2008; 158:243–50.
Human papillomavirus association with p16INK4A 
expression in penile lichen sclerosus and cancer
Human papillomavirus 
(HPV) infections are sex-
ually transmitted human 
carcinogens recognized 
to cause cervical can-
cer, that may play a role 
in the oncogenesis of 
penile cancer. This study 
shows a high prevalence 
of high-risk HPV infec-
tions in penile lichen 
sclerosus and cancer. 
HPV infection was associated with p16INK4A expression, con-
sistent with an active role for HPV in interfering with the Rb 
pathway. High-risk HPV infection could be involved in the 
tumorigenic process in 50% of penile cancers, and the use of 
prophylactic HPV vaccines has the potential to prevent these 
cancers. Br J Dermatol 2008; 158:261–5.
Establishing national admission standards for 
inpatient management of psoriasis
While hospital admis-
sion is still required 
for some patients 
with severe or unsta-
ble disease, in our 
current economic cli-
mate clinicians have 
to be responsive to 
use of costly resources. With the objective of determining fac-
tors predictive of length of stay for inpatients with psoriasis, 183 
patients were recruited in four dermatology centres in the U.K. 
and data collated on Psoriasis Area Severity Index (PASI) and 
other validated scoring systems. It was found that the admission 
PASI was significantly associated with length of stay (r = 0.2, P = 
0.02), whereas the other measures of disease severity were not. 
These data are a first step in defining disease-specific standards 
for inpatient length of stay. Br J Dermatol 2008; 158:266–72.
Long-term efficacy of infliximab in 
hidradenitis suppurativa
Several studies have 
reported efficacy of 
tumour necrosis fac-
tor-α inhibitors in 
hidradenitis suppu-
rativa (HS). Mekkes 
and Bos investigated 
for how long the 
positive effect of a 
short course of inf-
liximab persists. Ten 
patients were treated 
with three infusions and followed up for > 1 year. All patients 
improved within 2–6 weeks. After 1 year, a significant reduc-
tion of acne score and C-reactive protein, and improvement of 
quality of life was observed. The mean time until recurrence 
of lesions was 8.5 months, and three patients showed no 
recurrence during a 2-year follow up. It was concluded that 
infliximab is an effective treatment for severe HS, leading to 
reduction of symptoms for a prolonged period. Br J Dermatol 
2008; 158:370–4.
